Anemia is common in patients with chronic heart failure across the spectrum of ejection fraction and is a powerful predictor of rehospitalization rates and mortality (1) (2) (3) (4) (5) . Prevalence estimates vary widely according to heart failure severity, ranging from Ͻ10% in those with mild symptoms to Ͼ50% in those with advanced disease (6) . The etiology of heart failure-associated anemia is undoubtedly multifactorial, with posited contributions from the dilutional effects of volume overload, comorbid renal dysfunction and impaired erythropoietin production, iron deficiency, inflammation/ cytokine activation, malnutrition, and drug therapy (e.g., aspirin, angiotensin-converting enzyme inhibitors) (7) . Independent of the specific cause, a 1% decline in hematocrit has been linearly associated with a 3% increase in the risk of death (3, 5) Changes in hemoglobin concentration over time add prognostic information, with higher cardiovascular risk associated with persistent, incident, or worsening anemia over serial observation in ambulatory heart failure populations (4, 8) .
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Although nearly half of patients hospitalized with acute decompensated heart failure (ADHF) are anemic (9), the prognostic importance of hemoglobin concentration in this setting is less clear. Data from large registries and randomized controlled trials have returned mixed results, with anemia variably associated with short-term, but not longterm, mortality after adjustment for key confounders such as age, gender, and renal function (9 -13) . Because most heart failure admissions are related to congestive exacerbations as a consequence of progressive volume overload, discrepant findings in the studies of acute and chronic heart failure may reflect the greater relative contribution of transient hemodilution to anemia in the setting of heart failure decompensation. There are some circumstantial data to suggest this is true; the prevalence of anemia in studies of hospitalized heart failure patients exceeds that in the ambulatory setting, and plasma volume is known to be expanded in relation to heart failure severity (14) . As well, rising hemoglobin, or hemoconcentration, during decongestive treatment of acute heart failure decompensation has been associated with improved clinical outcomes (15, 16) .
In this issue of the Journal, van der Meer et al. (17) present important new information regarding the prognostic relevance of anemia and changing hemoglobin concentration during treatment for acute heart failure. Using a subset of 1,969 patients with acute heart failure, mildmoderate renal dysfunction, and serial hemoglobin measurements available over 7 days enrolled in the PROTECT (Placebo-Controlled Randomized Study of Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function) study, they examined the association between anemia, hemoconcentration, and mortality at 180 days. Several key findings are notable: similar to previous studies of ADHF, anemia as defined by the World Health Organization criteria (Ͻ13 g/dl for men, Ͻ12 g/dl for women) was present at baseline in 50.3% of subjects. During the first week of hospital treatment for heart failure, hemoglobin increased in 69.1% of subjects with an average rise of 0.3 Ϯ 0.7 g/dl. Hemoconcentration was associated with higher serum albumin, greater weight loss, and less residual congestion at day 7 (41.1% vs. 53.2%, p Ͻ 0.01), but also with worsening renal function. Despite the rise in serum creatinine with treatment, subjects with hemoconcentration experienced lower rates of all-cause mortality at 180 days than those without hemoconcentration. In multivariable analyses adjusted for age and renal function, the absolute change in hemoglobin, but not baseline hemoglobin, was associated with the risk for death (hazard ratio: 0.66; 95% confidence interval: 0.51 to 0.86; p ϭ 0.002).
Whether defined by filling pressures, physical examination findings, natriuretic peptide levels, or direct measurement of blood volume, volume overload is a powerful marker of risk in heart failure (18 -20) . Conversely, effective decongestion during acute heart failure decompensation is associated with improved clinical outcomes (21) (22) (23) . Although patients with hemoconcentration received a lower total dose of diuretics in this study, the associated albumin rise, weight loss, and improvement in clinical signs of congestion suggests they experienced more effective reduction in intravascular plasma volume with treatment. Acute hemoglobin changes during hemodialysis have long been used to guide volume removal during ultrafiltration; by analogy, rising hemoglobin over a longer time interval in the hospitalized heart failure patient may be a subtle marker of diuretic response. In this context, the observed association between hemoconcentration and improved clinical outcomes may in part reflect the results of more effective heart failure treatment. It is notable that patients with rising hemoglobin experienced better outcomes despite a slight rise in serum creatinine. In this way, these findings extend the results of other recent analyses emphasizing that resolution of congestion may be important even when it occurs at the expense of some deterioration in renal function. (15, 24) .
If hemoconcentration is a marker of effective volume removal with heart failure therapy and better outcomes, the failure to hemoconcentrate could be an ominous sign. Beyond changes in plasma volume, however, hemoglobin concentration during hospitalization may be affected by a number of other factors, including subclinical bleeding, medications, nutritional status, and serial phlebotomy for laboratory measurements. Although patients with severe anemia (hemoglobin Ͻ8 g/dl) or the need for transfusion were systematically excluded from the PROTECT study, those with less dramatic or subclinical bleeding may have been randomized. Accordingly, lack of hemoconcentration may not consistently reflect residual volume overload, and these data do not support routine intensification of diuretic therapy for patients in whom the hemoglobin fails to rise. Moreover, it is not clear from this analysis that all patients with hemoconcentration have reached a therapeutic limit or are completely dry. Because the rate of hemoglobin rise appears to be correlated with the rate of weight loss, rising hemoglobin may simply be a marker that the rate of intravascular volume depletion has exceeded the plasma refill rate from the interstitium. For patients with residual congestion by other measures, ongoing diuresis, perhaps at a slower rate, may be appropriate despite hemoconcentration.
As the investigators acknowledge, these data reflect the results of a post hoc analysis in a selected population with acute heart failure, renal dysfunction, and predominantly low ejection fraction from a randomized clinical trial. As with other subgroup analyses, the results are vulnerable to confounding and may not be easily generalized to the broader population with ADHF. Nonetheless, these observations expand the available literature regarding the prognostic implications of hemoglobin concentration in the acute heart failure setting. The lack of association between baseline anemia and mortality contrasts with prior studies in acute heart failure examining in-hospital or near-term mortality (9 -11) , but is consistent with the results of studies examining outcomes over a longer time horizon (12, 13) . Although better outcomes in those with hemoconcentration may in part be related to lesser severity of heart failure at baseline (suggested by the slightly better baseline renal function and lower diuretic requirement during hospitalization), similar results from the work of Testani et al. (15) in the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) trial suggest that this may be a robust finding. If so, taken together, these data support an important role for hemodilution as a significant contributor to anemia in patients with ADHF.
There is a need for considerable additional information before these findings could be used to guide clinical practice. The optimal time to assess hemoconcentration remains uncertain, because there is considerable variability in the diuretic response and the plasma refill rate from the extravascular space. The 7-day interval used in this analysis was arbitrarily selected based on the data that were available within the PROTECT study, and it is not clear whether assessment at a different time point (e.g., hospital discharge) would provide more relevant information. The optimal hemoglobin target for a given patient is uncertain, as it is difficult to quantify excess plasma volume without specialized technology; there is little guidance here about how much hemoconcentration is beneficial and whether there is a point of diminishing returns with continued rise in hemoglobin. It is notable that treatment guided by other indirect markers of volume status (natriuretic peptides, intrathoracic impedance) has in general not improved outcomes over care guided by the routine clinical assessment (25, 26) . Whether direct measurement of blood volume using novel radiolabeled dye dilution techniques will help direct more effective heart failure therapy is being tested in the ongoing TEAM-HF (Treating to Euvolemia by Clinical Assessment and Measured Blood Volume in Heart Failure) trial (27) .
In an era of increasing concern about rehospitalization and mortality following hospitalization for ADHF, additional levers to facilitate optimal in-hospital treatment are clearly needed. Although a number of questions remain, these data from van der Meer et al. provide support for the notion that anemia in the acute heart failure population may in part reflect the severity of volume overload. Hemoconcentration may follow on the effective relief of congestion and mark patients with a better prognosis. The association between hemoconcentration, but not baseline anemia, and prognosis seen here may be attributable to the dominant impact of effective decongestion on clinical outcomes. These data provide reassuring support for current guidelines recommending use of diuretics to restore normal volume status in patients with ADHF prior to discharge (28) and highlight that serial hemoglobin changes may be a useful adjunct to the standard clinical assessment in evaluating the response to therapy.
